MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marsh, J. D.
Right arrow Articles by Smith, T. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marsh, J. D.
Right arrow Articles by Smith, T. W.

Receptors for beta-adrenergic agonists in cultured chick ventricular cells. Relationship between agonist binding and physiologic effect

JD Marsh and TW Smith

To determine if the two-state, guanine nucleotide-modulated beta- adrenergic receptor model elucidated in erythrocyte membranes accurately describes hormone binding to intact heart cells, and to determine the relationship of agonist binding to physiologic contractile response, we studied beta-adrenergic antagonist and agonist binding to intact cultured heart cells and homogenates of these cells from embryonic chick ventricle and related the binding observations to alterations in amplitude of contraction of intact cells under identical conditions. The levo isomer of the beta-adrenergic antagonist pindolol was radioiodinated, purified, and utilized to characterize the beta- adrenergic receptor in intact, beating heart cells under physiologic conditions. Computer analysis of iodopindolol-binding isotherms revealed a KD = 22 +/- 3 pM with Bmax = 10.3 fmol/mg of protein in intact cells; in homogenates of cells, the KD was 39 +/- 12 pM in the absence of exogenous guanine nucleotides and 19 +/- 7 pM in their presence. Estimation of the dissociation constant for iodopindolol binding to intact cells by kinetic methods yielded KD = 64 pM. Binding was stereospecific, saturable, and identified a beta 1-adrenergic receptor. Computer modeling of agonist competition curves indicated a single receptor state in intact cells with KD = 0.28 microM for isoproterenol. However, in cell homogenates, two receptor states for agonists were identified with the high affinity state of the receptor having a KD = 3 nM. Addition of guanine nucleotides to the cell homogenate reverted the receptor to a single state similar to that in intact cells. Under nonequilibrium binding conditions, a high affinity state for agonist was detected in intact cells with IC50 = 1.1 nM. The EC50 for isoproterenol-enhanced contractility was 6 nM and EC50 for cAMP response was 4 nM. At the isoproterenol concentration causing 50% maximal inotropic response, 67% occupancy of high affinity receptors occurs. Thus, there is a close relationship between high affinity receptor occupancy and augmentation of contractility in intact cells. These findings support the view that agonist interaction with the guanine nucleotide-sensitive, high affinity receptor state initiates the physiologic response of myocardial tissue to beta-adrenergic agonists.

Volume 27, Issue 1, pp. 10-18, 01/01/1985
Copyright © 1985 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
C. Pavoine, S. Magne, A. Sauvadet, and F. Pecker
Evidence for a beta 2-Adrenergic/Arachidonic Acid Pathway in Ventricular Cardiomyocytes. REGULATION BY THE beta 1-ADRENERGIC/cAMP PATHWAY
J. Biol. Chem., January 8, 1999; 274(2): 628 - 637.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1985 by the American Society for Pharmacology and Experimental Therapeutics